These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31357507)

  • 1. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
    Xiao Y; Meierhofer D
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.
    Zhang L; Hobeika CS; Khabibullin D; Yu D; Filippakis H; Alchoueiry M; Tang Y; Lam HC; Tsvetkov P; Georgiou G; Lamb C; Stone E; Puigserver P; Priolo C; Henske EP
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2122840119. PubMed ID: 35867762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
    Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
    Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and clinical value of SALL4 in renal cell carcinomas.
    Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
    Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms.
    Petit A; Castillo M; Santos M; Mellado B; Alcover JB; Mallofré C
    Am J Surg Pathol; 2004 May; 28(5):676-8. PubMed ID: 15105658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
    Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network-based metabolic characterization of renal cell carcinoma.
    Pandey N; Lanke V; Vinod PK
    Sci Rep; 2020 Apr; 10(1):5955. PubMed ID: 32249812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
    Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
    Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters.
    Tsai WC; Sheu LF; Nieh S; Yu CP; Sun GH; Lin YF; Chen A; Jin JS
    World J Urol; 2007 Mar; 25(1):73-80. PubMed ID: 17021824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
    DiNatale RG; Sanchez A; Hakimi AA; Reznik E
    Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
    Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
    Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
    BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma.
    Priolo C; Khabibullin D; Reznik E; Filippakis H; Ogórek B; Kavanagh TR; Nijmeh J; Herbert ZT; Asara JM; Kwiatkowski DJ; Wu CL; Henske EP
    Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6274-E6282. PubMed ID: 29891694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
    Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
    Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
    Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
    J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.